Get the latest news, insights, and market updates on VCYT (Veracyte, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Veracyte (VCYT) Turns Profitable, But Significant $27M Loss Challenges Bullish Narratives
Veracyte (VCYT) recently moved into profitability, with its net profit margin turning positive even as a significant, non-recurring loss of $27.0 million affected the latest twelve-month results to September 30, 2025. Over the past five years, the company’s annual earnings growth stood at 29.3%. Looking ahead, analysts expect earnings to rise at a robust 26.6% per year, outpacing the broader US market’s 16% growth forecast. Revenue is projected to grow at 10.1% per year. For investors, the... Nov 6, 2025 - $VCYT
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., November 06, 2025--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Nov 6, 2025 - $VCYT
Veracyte: Q3 Earnings Snapshot
The South San Francisco, California-based company said it had profit of 24 cents per share. Earnings, adjusted for one-time gains and costs, were 51 cents per share. The results surpassed Wall Street expectations. Nov 4, 2025 - $VCYT
Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +59.38% and +5.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 4, 2025 - $VCYT
Veracyte Announces Third Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., November 04, 2025--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. Nov 4, 2025 - $VCYT
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
SOUTH SAN FRANCISCO, Calif., November 03, 2025--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool’s ability to help define the future of thyroid nodule evaluation. Using the company’s innovative whole-transcriptome-derived research-use-only platform, researchers analyzed molecular data from thyroid nodules to develop signatures with potential Nov 3, 2025 - $VCYT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple